Salix Pharmaceuticals, Ltd.

396 articles about Salix Pharmaceuticals, Ltd.

• Salix Provides Notice Of Anticipated Make-Whole Fundamental Change To Holders Of Its 1.5% Convertible Senior Notes Due 2019

  2/26/2015

• Spending Spree Continues as Valeant Officially Snags Salix for $14.5 Billion

  2/23/2015

• EXCLUSIVE: Evercore ISI Breaks Down Valeant / Salix Deal By the Numbers

  2/23/2015

• Endo Pharmaceuticals Rumored to be Battling Shire, Valeant for Salix's Affections

  2/18/2015

• Salix Announces 4Q And FY2014 Financial Results Conference Call And Webcast

  2/16/2015

• Look Out Valeant, Shire Wants to Continue Spending Spree With Salix Bid

  2/16/2015

• Valeant Secures Financing to Make Rumored $9.6 Billion Bid for Salix

  2/13/2015

• Deal-Hungry Valeant Eyes Salix Pharmaceuticals, Ltd. as Its Latest Takeover Target

  2/5/2015

• Napo Pharmaceuticals, Inc. Files Brief On Appeal In Dispute With Salix Pharmaceuticals, Ltd.

  2/3/2015

• Salix Pharmaceuticals, Ltd. Announces The Promotion Of William P. Forbes, PharmD To President, Medical, R&D And Chief Development Officer

  2/2/2015

• Salix Pharmaceuticals, Ltd. Provides Update On Audit Committee Review

  1/29/2015

• Salix Pharmaceuticals, Ltd. Overstated Revenue and Income by Millions: Audit

  1/29/2015

• Plagued By Inventory Problems, Salix Pharmaceuticals, Ltd. Finally Brings In Advisors to Explore Sale

  1/21/2015

• Pharming Group And Salix Pharmaceuticals, Ltd. Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema

  1/8/2015

• Salix Pharmaceuticals, Ltd. CEO to Retire Amid Inventory Pile Up Drama

  1/6/2015

• Carolyn Logan To Retire As Chief Executive Officer Of Salix Pharmaceuticals, Ltd.

  1/6/2015

• Hedge Fund Takes Stake In Salix Pharmaceuticals, Ltd.; Other Top Investors Push For Sale Of Company

  12/19/2014

• Salix Pharmaceuticals, Ltd. Vows To Fix Inventory Pile-Up Problem By End Of 2015

  12/16/2014

• Salix Pharmaceuticals, Ltd. Provides Updates On Wholesaler Inventory Reductions And The XIFAXAN® 550 For IBS-D Approval Timeline, And Provides Preliminary Guidance For 2015 And 2016

  12/16/2014

• Salix Pharmaceuticals, Ltd. Announces Plan To Augment Board Of Directors

  11/25/2014